Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PDA Closure Set from Japan Lifeline Recommended for Approval
December 15, 2008
- Chugai, Chiome Sign Agreement on Monoclonal Antibody Production
December 15, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 15, 2008
- BUSINESS NEWS IN BRIEF
December 15, 2008
- SURVEY／Diabetes Is Most Commonly Examined
December 15, 2008
- Wholesalers Should Talk with Manufacturers on Equal Footing: Mr Negi
December 15, 2008
- JSMO to Prepare GL for KRAS Gene Mutation Testing
December 15, 2008
- Sales Up, Profits Down for Generic Companies as a Whole in FY2007
December 15, 2008
- Appropriate Diagnosis of Sleep Disorders by Specialists Necessary: NBI Seminar
December 15, 2008
- Over 40% of Pharmacists Unsatisfied with Generic Houses' Call Center Services
December 15, 2008
- Opinions Divided within LDP on Tobacco Tax
December 15, 2008
- Earlier Approval Is More Important than Risk of Problems due to Ethnic Differences
December 15, 2008
- NHI Pricing Recommended for Approval for 9 APIs
December 15, 2008
- Precautions Needed for Infections in Treating RA with Actemra: PMS Data
December 15, 2008
- 2 Combinations of ARB and Diuretic Recommended for Approval
December 15, 2008
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- Research on Biomarkers Essential to Develop Anticancer Drugs: Dr Inoue
December 15, 2008
- Pfizer to Break Dependence on Blockbusters: Mr Iwasaki
December 15, 2008
- Tripartite Collaboration Needed to Bring Benefits of iPS Cells to Patients: Prof. Yamanaka
December 15, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…